In conclusion, the positive results of both PDE4 and PDE7 inhibition in MS are interesting to ischemic stroke research because they suggest that combined PDE4 and PDE7 inhibition can be employed as potential therapeutic strategy in ischemic stroke. This evidence concerns the gene PDE7A and myeloid sarcoma.